Lynch interception is the harder vaccine trial, and Nouscom just funded it
An oversubscribed EUR 120M Series D sends an off-the-shelf cancer vaccine toward a prevention trial measured in colonoscopy results from dozens, not thousands, of patients.
Cancer vaccine programs have usually tried to treat tumors that already exist. Nouscom is asking a slower question: whether an off-the-shelf neoantigen immunotherapy can intercept cancer in Lynch syndrome carriers who do not yet have a tumor to shrink.
On 19 Oct 2026 the clinical-stage company closed an oversubscribed EUR 120 million ($135 million) Series D, according to a company release. The round was co-led by M Ventures and Revelation Partners, with new investors Angelini Industries, the European Investment Bank (through its Aurea facility), and Neva SGR (Intesa Sanpaolo Group), plus existing investors including 5AM Ventures, Andera Partners, Bpifrance, EQT Life Sciences, and Versant Ventures. Proceeds are meant to take NOUS-209 through a single global registration-enabling clinical trial for cancer interception in Lynch syndrome carriers. The U.S. Food and Drug Administration has granted the candidate Fast Track designation.
A genetically defined population, not a late tumor
Lynch syndrome is caused by germline mutations in DNA mismatch repair genes. It affects roughly 1 in 300 people and carries a lifetime cancer risk as high as 80%, per a trial abstract. Fierce Biotech cites a 50-80% lifetime colorectal cancer risk and a 40-60% endometrial cancer risk. That mix of high lifetime risk and routine endoscopic surveillance is why the indication is attractive, and why it is hard. Prevention studies run long, cost a lot, and hang on advanced adenomas and cancers rather than radiographic tumor shrinkage.
Shared frameshift peptides, not a per-patient construct
NOUS-209 is an off-the-shelf neoantigen immunotherapy that delivers 209 shared frameshift peptides using a heterologous prime-boost of a great ape adenovirus (GAd20) and modified vaccinia virus Ankara (MVA), as described in a Nature Medicine paper. The construct is built around neoantigens that recur across individuals, rather than a new product for each patient.
Merck and Moderna's mRNA-4157 is personalized per patient. Nouscom also has a personalized program, but off-the-shelf NOUS-209 has been the priority since a EUR 42 million round in 2017, Fierce reported. An off-the-shelf vector is simpler to manufacture and dose. It also has to be right about which shared frameshift peptides matter in a genetically defined but still heterogeneous carrier population.
Immune responses in nearly every evaluable patient
The Phase 1b/2 study is single-arm. Cohort 1 enrolled 45 participants across MD Anderson, the University of Puerto Rico, Fox Chase Cancer Center, and City of Hope, within the NCI iCAN PREVENT consortium, according to the Nature Medicine paper.
In 45 participants there were no intervention-related serious adverse events. Injection-site reactions of any grade occurred in 91% after the prime and 76% after the boost, with no grade 3 events. Fatigue of any grade occurred in 80% after the prime and 53% after the boost, including 4% grade 3, the PubMed abstract states.
Neoantigen-specific T-cell responses appeared in 100% of 37 evaluable participants, with a mean peak of roughly 1,100 interferon-gamma spot-forming cells per million PBMCs. Responses were durable at 1 year in 85% of participants. Both CD8+ and CD4+ T cells were induced and recognized multiple frameshift peptides. More than 100 immunogenic frameshift peptides were identified, and cytotoxic activity was demonstrated in vitro, the same abstract notes. That is a coherent immune story. It is still an immune story, not a completed prevention result.
Year-2 colonoscopy data from 17 people
The intercept claim sits in a company release on an ESMO abstract (3438O), to be presented 23-27 Oct 2026 in Madrid by Eduardo Vilar-Sanchez of MD Anderson: all evaluable Lynch syndrome carriers dosed with NOUS-209 remained free of advanced adenomas and colorectal cancer at colonoscopy after year 1 (n=43) and year 2 (n=17).
Those denominators are the real constraint. Forty-three people at year 1 and 17 at year 2, in a single-arm study, cannot carry a registration decision by themselves. Zero advanced adenomas and colorectal cancers in a small, intensively surveilled cohort is the signal investors just paid for. It is also the kind of early, uncontrolled readout that can fade once follow-up is longer, broader, and global.
Fast Track designation can tighten the regulatory conversation. It does not compress years of colonoscopy. The biology lines up: shared frameshift peptides, T-cell responses in every evaluable participant, in vitro cytotoxicity, and no intervention-related serious adverse events. The round was oversubscribed. What remains is whether that early intercept signal can survive the slow, expensive registration path the Series D is supposed to fund.